Get the Weekly Intelligence Brief — top committee picks every Sunday.

ABBV vs LLY

AbbVie vs Eli Lilly and Company — AI-powered side-by-side comparison
ABBV
AbbVie
58
Buy
VS
LLY
Eli Lilly and Company
53
Watch
MetricABBVLLY
AI Score 58 53
Price $256.35 $1,148.47
P/E Ratio 72.22× 38.47×
ROE -129.2% 77.8%
Revenue Growth YoY
Gross Margin 71.5% 84.0%
Debt / Equity -11.93× 1.62×
Dividend Yield 2.7% 0.6%
RSI (14) 43.8 29.9
Beta 0.281 0.502
Expected Upside +4.3% +8.7%

AI Committee View

Current Innellis committee reasoning for ABBV versus LLY.
ABBV leads by 5 points.

ABBV scores 58/100 (Buy) versus LLY at 53/100 (Watch).

ABBV Committee View
50% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 20.19) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • ROE of 95.6% shows genuine earnings power backing the valuation — Value
  • Dividend yield of 4.5% pays you to wait — Value
  • EPS growing 67.6% YoY — Growth
Bear Case
  • P/E of 71.8 is expensive by classic value standards — Value
  • Price-to-book of 94.4x prices in significant intangible value — Value
  • Debt-to-equity of 20.19 adds balance-sheet risk to the value case — Value
LLY Committee View
50% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 1.60) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • ROE of 92.6% shows genuine earnings power backing the valuation — Value
  • Revenue growing 49.6% YoY -- genuine top-line momentum — Growth
  • EPS growing 94.6% YoY — Growth
Bear Case
  • P/E of 40.5 is expensive by classic value standards — Value
  • Price-to-book of 38.3x prices in significant intangible value — Value
  • Debt-to-equity of 1.60 adds balance-sheet risk to the value case — Value
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ABBV Full Analysis LLY Full Analysis